|

Deucravacitinib Clinical Trials

3 actively recruiting trials across 2 locations

▲ +1 trial since August 2026

Pipeline

Phase 3: 1Phase 4: 1

Top Sponsors

  • Bristol-Myers Squibb2
  • University of Texas Southwestern Medical Center1

Indications

  • Arthritis2
  • Juvenile Psoriatic Arthritis1
  • Psoriatic Arthritis (PsA)1
  • Psoriasis1
  • Cancer1

Other1 trial

Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Lancaster, California1 trial

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Local Institution - 0038

Phase 3

Dallas, Texas1 trial

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

UT Southwestern Medical Center

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.